• Technology
  • Patients
  • Investors
  • About Us
  • News
Hypersound Medical Files for Provisional Patent with the United States Patent Office

Hypersound Medical Files for Provisional Patent with the United States Patent Office

by roumianad | Feb 1, 2022 | News

Hypersound Medical announced that it has filed with the United States Patent Office for a provisional patent for its groundbreaking microwave technology. The innovative technology is approaches pain management in a non-surgical, non-invasive, cost-effective way. Since...
Hypersound Medical Files for Provisional Patent with the United States Patent Office

Hypersound Medical Incorporates to Bring Exciting New Technology to Market

by roumianad | Jan 29, 2021 | News

Tim Dickman, Co-Founder and Chief Executive Officer, announced the incorporation of Hypersound Medical. The company has developed a breakthrough non-invasive device to help patients alleviate acute and chronic pain. This represents a significant breakthrough in the...
Next Entries »

Recent Posts

  • Clinical Milestone Achieved: Positive Early Human Trial Results for Hypersound RF Pain Management Device
  • Hypersound Medical Placed on the National Science Foundation’s Fast-Track program
  • Hypersound Medical Featured in IEEE Pulse for Breakthrough Non-Invasive Chronic Pain Therapy
  • Hypersound Medical Selected Among the 25 Semifinalists for the 2024 Arizona Innovation Challenge
  • Hypersound Medical Receives Funding through Arizona’s Small Business Administration’s Federal and State Technology Partnership Program

Recent Comments

No comments to show.

Leading the way in effective, non-invasive, affordable pain management technology.

Technology

Patients

Investors

About Us

Company News

Contacts

Privacy Policy

Copyright © 2026Hypersound Medical. All Rights Reserved.

CAUTION: Investigational Device. Limited by Federal (or United States) law to investigational use. The Hypersound device is not intended to diagnose, treat, cure, or prevent any disease. It is currently in the process of being evaluated by FDA.